Autologous cultured kidney tissue cells - RegenMedTX

Drug Profile

Autologous cultured kidney tissue cells - RegenMedTX

Alternative Names: Autologous cultured kidney tissue cells - Tengion; Autologous Neo-Kidney augment - RegenMedTX; Neo-Kidney Augment; NKA - RegenMedTX

Latest Information Update: 16 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Tengion
  • Developer RegenMedTX
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Kidney disorders

Most Recent Events

  • 01 Aug 2017 RegenMedTX completes a phase II trial for Kidney disorders in USA (Parenteral) (NCT02525263)
  • 01 Sep 2016 RegenMed initiates enrolment in a phase II trial for Kidney disorders in USA (NCT02836574)
  • 01 Jul 2016 Phase-II clinical trials in Kidney disorders in USA (Parenteral) (NCT02525263)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top